LKPC(SH:600789)2025-01-26 07:50Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between 350 million and 415 million CNY, representing a year-on-year increase of 42% to 69%[2] - The projected net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is estimated to be between 192 million and 225 million CNY, reflecting a year-on-year increase of 10% to 29%[3] - The previous year's net profit attributable to shareholders of the parent company was 246.17 million CNY, with a total profit of 272.98 million CNY[4] Revenue Growth - The company has achieved significant growth in sales revenue of its leading products due to ongoing performance management and product technology upgrades[5] - The company has received approval for 32 new generic drug registrations since 2021, contributing to rapid revenue growth from new products[5] Land Compensation - The land compensation amount from the transfer of the southern plant area is estimated to be 337.57 million CNY, with a pre-tax gain from land storage expected to be 155.84 million CNY after deducting related expenses[5] Performance Forecast Accuracy - The company emphasizes that there are no significant uncertainties affecting the accuracy of this performance forecast[6] - The forecast data is preliminary and subject to final audited financial results in the 2024 annual report[7]